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Abstract
Background: Gastric hepatoid adenocarcinoma (HAC) is a special type of gastric cancer that morphologically
mimics hepatocellular carcinoma. In this study, we performed an evaluation of clinicopathologic characteristics,
treatment outcome, and prognosis in patients with gastric HAC.
Methods: We consecutively enrolled patients with pathologically proven gastric HAC at Seoul National University
Hospital between January 1996 and December 2008 and conducted a retrospective review. Among 15,253 patients
with gastric cancer, 26 patients (0.17%) were diagnosed as gastric HAC.
Results: Among 26 patients, 22 were male and the median age was 63. Stage at diagnosis was stage IB in 3 patients,
stage II in 6 patients, stage III in 7 patients, and stage IV in 10 patients. Eight patients out of 18 patients with stage IB, II,
III, and IV relapsed after curative surgery. Relapse-free survival for these patients was 16.67 months. The most common
metastatic site was intraabdominal lymph nodes (n = 9), followed by the liver (n = 8). Thirteen patients received
palliative chemotherapy. The most commonly used regimen was a combination of fluoropyrimidine and platinum.
Partial response was observed in one patient and stable disease in 5 patients. Median overall survival and progression
free survival of these patients were 8.03 (95% CI: 6.59-9.47) and 3.47 months (95% CI: 0.65-6.29), respectively.
Conclusions: Gastric HAC is a very rare but unique type of stomach cancer. Early detection of this type of cancer
is of critical importance to patient prognosis. Additional studies to reveal the biology of this tumor are warranted.
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Background
Hepatoid adenocarcinoma (HAC) showed a histologic
appearance typical of hepatocellular carcinoma, including
solid, trabecular, and pseudograndular structures; tumor
cells were round or polygonal in shape [1]. HACs have
been described in several different organs, including the
lung, pancreas, esophagus, ampulla of Vater, colon, urin-
ary bladder, renal pelvis, ovaries, uterus, and cervix
[2-12]. The stomach is the organ in which HAC has been
most commonly identified. Incidence of HAC is known
to be 0.38-0.73%, as reported in a previous study [1,13].
Alpha-fetoprotein (AFP) is a fetal serum protein pro-
duced by fetal liver and yolk sac cells, and by some fetal
gastrointestinal cells [14]. In adults, serum AFP is elevated
in patients with hepatocellular carcinoma, yolk sac tumors,
and noncancerous liver disease. AFP-producing tumors
have been reported in several different organs [5-7]. The
stomach is one of the most common sites affected by
these tumors, and the first such case has been described
[15]. Later, Ishikura et al. proposed the term “hepatoid
adenocarcinoma (HAC) of the stomach” for primary gas-
tric carcinoma characterized histologically by hepatoid dif-
ferentiation and production of large amounts of AFP [16].
However, he reported observation of primary AFP-
negative gastric carcinomas with characteristic histologic
features mimicking hepatocellular carcinoma [17].
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tric carcinoma showing hepatic differentiation without
production of AFP. In progression, Nagai et al. noted that
diagnosis of HAC of the stomach was not dependent on
production of AFP, and suggested that diagnosis should be
based on recognition of characteristic histologic features
[13].
HACs of the stomach have been known as a rare sub-
type; therefore, previously reported case reports or case
series have focused on aggressiveness or diagnosis,
rather than treatment outcome. Information has been
very limited. In this study, we conducted an evaluation
of clinicopathologic characteristics, treatment outcome,
and prognosis in patients with gastric HAC.
Methods
A computer search of pathology reports was performed
for identification of pathologically confirmed hepatoid
adenocarcinoma of the stomach from January 1996 to
December 2008 in Seoul National University Hospital.
Among 15,253 patients with newly diagnosed stomach
cancer during this period, 26 patients had hepatoid ade-
nocarcinoma in their pathology reports.
Diagnosis of HAC was dependent on morphologic fea-
tures. Pathological diagnosis of 23 patients was made pri-
marily by examination of gastrectomy specimens showing
histological observations that included specific hepatoid
structures, such as the trabecular, pseudo-grandular pat-
tern and hyaline globules; other patients who did not
undergo gastrectomy but were strongly suggestive of HAC
by biopsy specimens were confirmed by immunohisto-
chemical (IHC) staining (anti-AFP, anti-hepatocyte, alpha-
1-antitrypsin) positive and elevated serum AFP level. Inci-
dence of gastric HAC accounts for 0.17% of all gastric
cancers.
Pathology reports, medical records, and imagings were
reviewed. Clinicopathologic data obtained included age,
sex, endoscopic finding, histopathologic characteristics
(tumor location, IHC staining, serum AFP levels, history
of chronic hepatitis, stage at diagnosis, treatment modal-
ity, and overall survival. According to the 7
th edition of
the American Joint Committee on Cancer (AJCC), stage
of tumor was reclassified.
To determine the prognosis of patients with HAC, we
assessed relapse free survival (RFS) and overall survival
(OS). The starting point of RFS in early or locally
advanced malignancy was the first day of surgery, and the
starting day of OS was the day of diagnosis. Patients with
advanced or relapsed cancer were assessed for overall
survival and tumor response to palliative chemotherapy.
For evaluation of outcome of palliative chemotherapy,
the starting point for overall survival (OS) and progres-
sion free survival (PFS) in patients receiving palliative
chemotherapy was the first day of chemotherapy. The
Kaplan-Meier method was used for estimation of RFS,
PFS, and OS. Statistical comparisons and 95% confidence
interval were made using an SPSS software package
version 13.0.(SPSS Ins., Chicago, IL USA). Tumor
response was evaluated according to the Response
Evaluation Criteria for Solid Tumors (RECIST).
All patients gave informed consent prior to gastro-
scopy, surgery, or chemotherapy, and every procedure
was performed according to the rules of good clinical
practice. This study was approved by the institutional
review board of Seoul National University Hospital (IRB
No:0911-064-301).
Results
1) Clinicopathologic features of hepatoid adenocarcinoma
(HAC) of the stomach
A total of 26 patients were enrolled. Twenty-two patients
were male (median age, 63.4 years; range 36.4-74.1 years).
Only one patient had chronic hepatitis B. Stage at diagno-
sis was stage IB in 3 patients, stage II in 6 patients, stage
III in 7 patients, and stage IV in 10 patients.
In endoscopic findings, Bormann type 3 was the
most common (n = 11), followed by Bormann type 2
(n = 5). Four patients showed the early type of gastric
cancer. Tumors occurred mainly at the lower-third,
particularly the antrum (n = 16, n = 13, respectively).
In IHC, 15 patients were positive for AFP (Dakopatts,
Denmark). Only one of four patients with negative
AFP was assessed for alpha-1-antitrypsin (Dakopatts,
Denmark) and the result was positive. Serum AFP was
accessible in 11 patients, of whom 7 patients had ele-
vated levels, and median serum AFP was 208 ng/mL
(range 5- 4,750,000 ng/mL) (Table 1).
Of 23 patients who underwent gastrectomy, 21
patients could be evaluated for findings of endovascular
or endolymphatic tumor emboli. Of those, 71% had
endovascular tumor emboli and 71% had endolymphatic
tumor emboli in surgical specimens (Table 2). Of 8
patients who did not show recurrence, two patients had
endovascular tumor emboli and three patients had
endolymphatic tumor emboli. Almost all stage IV
patients, except for one patient with only vascular
tumor emboli, who underwent gastrectomy, had both
endovascular and endolymphatic tumor emboli in surgi-
cal specimens.
2) Treatment pattern and clinical outcomes for all cases
of hepatoid adenocarcinoma (HAC) of the stomach
Figure 1 shows the treatment pattern for all patients. Six-
teen patients were diagnosed early or as locally advanced
stage and ten patients showed distant metastasis at diag-
nosis. Of 18 patients undergoing curative resection, 9
patients underwent adjuvant chemotherapy and the other
9 patients did not receive adjuvant chemotherapy due to
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patient refusal (n = 2), early relapse (n = 1), and death
(n = 1). Two patients with stage II, five patients with
s t a g eI I I ,a n do n ep a t i e n tw i t hs t a g eI Vr e l a p s e da f t e r
curative surgery. Median follow-up duration was 61.4
months (range 4.8-139.5 months). Nine patients, includ-
ing three patients with stage Ib, three patients with stage
II, one patient with stage III, and 2 patients with stage IV,
were disease-free. Two patients expired due to post-
operative complications (delayed bleeding and sepsis). Of
10 patients who initially had stage IV, 7 patients under-
went gastrectomy and 6 patients, including 3 non oper-
able patients, received palliative chemotherapy. Two of
three stage IV patients who underwent gastrectomy with
R0 resection and metastatectomy were followed up with
no evidence of disease, and the other was treated with
palliative chemotherapy after recurrence at postoperative
9.2 months. Seven patients of 16 patients with initial
stage I-III relapsed and six patients received palliative
chemotherapy.
Relapse-free median survival of patients who under-
went curative resection was 16.67 months (range 1.63-
65.9) (figure 2). Median overall survival of stage I-III
and stage IV were 28.0 and 8.2 months, respectively
(range 2.9 - 66.0 months, 2.1 - 60.87 months) (figure 3).
The survival difference between both group was margin-
ally significant (p = 0.068).
Overall survival of 18 patients with metastatic or
recurrent cancer was 9.63 months (95% CI: 4.34-14.92,
range: 1.20- 60.87 months).
3) Outcomes of palliative chemotherapy in metastatic/
recurrent hepatoid adenocarcinoma (HAC) of the stomach
Ten patients had metastatic HAC and 8 had recurrent
HAC, of whom 13 patients were treated with palliative
chemotherapy. The most common metastatic site was
lymph nodes (n = 9), followed by liver (n = 8), and peri-
toneal seeding (n = 3). Portal vein thrombosis was iden-
tified in eight patients.
The most commonly used regimen was a combination
of fluoropyrimidine and platinum (n = 7), followed by a
combination of paclitaxel and cisplatin, and TS-1 single
(respectively n = 2, n = 2)(Table 3). Evaluation of
response rate was possible in 12 of 13 patients treated
with palliative chemotherapy. One showed partial
response and five patients showed stable disease; the
response rate was 8.3% and the disease control rate was
50% (95% CI: 25.4 -74.6).
OS and PFS of 13 patients receiving palliative che-
motherapy were 8.03 and 3.47 months, respectively
(95% CI: 6.59-9.47, range: 0.63-40.8 months, 95% CI:
0.65-6.29, 0.63 - 35.43 months, respectively) (Figures 4
and 5).
Discussion
In this study, incidence of HAC was 0.17%, which is
relatively lower than 0.38-0.73%, which was reported in
a previous study [1,13]. Lower incidence of our study is
associated with difficulty in diagnosis of this neoplasm.
HAC is a rare type of gastric adenocarcinoma and other
typical diagnoses should be ruled out. Diagnosis of HAC
often required microscopically minute observation and
IHC study, including anti-hepatocytes, anti-AFP, and
Table 1 Clinicopathologic characteristics of all 26
patients
Characteristics No of patient %
Age, median = 63.4 (36.4-74.1)
30- 60 10 38.5%
> 60 16 61.5%
Sex (n = 26)
Male 22 84.6%
Female 4 12.5%
Stage at diagnosis (n = 26)
Stage IB 3 11.5%
Stage II 6 23.1%
Stage III 7 26.9%
Stage IV 10 38.5%
Endoscopic finding (n = 23)
Borrmann type I 2 8.7%
Borrmann type II 5 21.7%
Borrmann type III 11 47.8%
Borrmann type IV 1 4.3%
EGC
† 4 17.4%
Location (n = 25)
Upper-third 2 8.0%
Middle-third 5 20.0%
Lower-third 16 64.0%
Whole stomach 2 8.0%
Immunohitstochemical staining (n = 26)
AFP (positive/negative/
‡NA) 15/4/7
Anti-hepatocyte (positive/negative/
‡NA) 4/4/18
Anti-chymotrypsin (positive/negative/
‡NA)
1/1/24
Serum AFP (n = 26)
Elevated (median, range) 7 ( 208 ng/ml,
5-4,750,000 ng/
ml)
Normal 4
‡NA 15
† Early gastric cancer type,
‡Not assessed.
Table 2 Pathologic and laboratory findings
Finding % (No of patient)
Present Not
present
Not
assessed
Endolymphatic tumor emboli (n = 23) 15 6 2
Endovascular tumor emboli (n = 23) 15 6 2
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88% underwent gastrectomy. Only three patients were
diagnosed with HAC without gastrectomy. It is possible
that most patients who were diagnosed by biopsy only
and who did not require surgery were not included.
Primary gastric cancer could show elevated serum
AFP of gastric production of primitive foregut origin,
such as the liver, and AFP produced hepatic metastatic
lesions; reported incidence of AFP producing gastric
cancer has been from 1.3-15% of all cases of gastric
cancer. In the early days of HAC definition, it was sug-
gested that HAC developed from AFP-producing gastric
cancer in which extensive hepatoid differentiation rarely
occurred because not all AFP-producing gastric cancers
resemble hepatocellular carcinoma [18]. Later, Ishikura
et al. reported on primary AFP-negative gastric carcino-
mas with characteristic histologic features mimicking
hepatocellular carcinoma [17]. Moreover, Nagai et al.
reported that 46% of gastric HACs showed negatively
stained AFP and that microscopically hepatoid features,
regardless of AFP-staining, were more important for
prognosis [13]. In their study, all patients with negatively
AFP-stained gastric HAC and accessible serum AFP had
Figure 1 Treatment patterns for all patients. Stage at diagnosis was stage IB in 3 patients, stage II in 6 patients, stage III in 7 patients, and
stage IV in 10 patients. Nine patients, including three patients with stage Ib, three patients with stage II, one patient with stage III, and 2
patients with stage IV, were cured. Two patients expired due to post-operative complications. Of 10 patients who initially had stage IV, 6 patients
underwent gastrectomy and 6 patients received palliative chemotherapy. Two of three stage IV patients who underwent gastrectomy with R0
resection were followed up with no evidence of disease. Seven patients of 16 patients with initial stage I-III relapsed and six patients received
palliative chemotherapy.
Figure 2 Kaplan-Meier plot of RFS to early or locally advanced
gastric HAC. Median RFS of patients who underwent curative
resection was 16.67 months (range 1.63- 65.9)(Vertical upticks
represent alive patients).
Figure 3 Kaplan-Meier plot of OS according to stage.M e d i a n
OS of stage I-III and stage IV were 28.0 and 8.2 months, respectively
(range 2.9 - 66.0 months, 2.1 - 60.87 months, p = 0.068) (Vertical
upticks represent alive patients).
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Page 4 of 7normal serum AFP levels. Therefore, gastric cancer
showing hepatic differentiation without production of
AFP was a clinicopathologic entity of HAC.
In gastric HAC, blood vessel and lymphatic permea-
tion and regional lymph node metastasis occurred more
frequently than in poorly differentiated gastric adenocar-
cinoma and primary HCC, and these were associated
with a poorer prognosis [1,17]. In our study, of 23
patients who underwent gastrectomy, 71% had endovas-
cular tumor emboli, which was lower than that of a pre-
vious study [1]. None of the patients with stage IB had
microscopically endovascular or endolymphatic invasion
and they did not relapse (median follow up = 61.37
months, range 25.8 - 63.0 months). Six of eight patients
who did not relapse did not have endovascular invasion,
which may be a good predictor of relapse, although vali-
dation will be required. Therefore, diagnosis of gastric
HAC at an earlier stage may lead to a better prognosis.
The survival difference between stage I-III and stage IV
was marginally significant, which might result from
small number of patients.
According to a randomized trial for first-line therapy
for treatment of advanced gastric cancer, response rate
of 1
st line chemotherapy is about 32-46% and OS of
stage IV stomach cancer is 9.3-10.5 months [19]. In this
study, median OS is 8.03 months, which is much longer
than that of previous reports that included five patients
[20].
Table 3 Clinicopathologic characteristics of patients
receiving palliative chemotherapy
Characteristics (n = 13) No of patient %
Age, Median: 59 (36-74)
Sex
Male 12 92.3%
Female 1 7.7%
ECOG PS
0-1 11 84.6
2 2 15.4
Stage
Stage IV at diagnosis 6 46.2%
Recurred cancer 7 53.8%
Portal vein thrombosis
Yes 8 61.5%
No 5 38.5%
Metastasis
LN 9 69.2%
Liver 8 61.5%
Peritoneal seeding 3 23.1%
Pancreas 2 15.4%
lung 1 7.7%
Gastrectomy
Yes 10 76.9%
No 3 23.1%
Number of metastatic organ
1-2 8 61.5%
> 3 5 38.5%
Chemotherapy
Up to 1
st line 13 100%
Up to 2
nd line 7 53.8%
Up to 3
rd line 1 7.7%
Chemotherapeutic agent
FP/XP/FOLFOX
† 7 53.8%
TP
‡ 2 15.4%
TS-1 2 15.4%
Others (FL
§,F M
¶) 2 15.4%
†cisplatin and 5-FU/capecitabine and cisplatin/oxaliplatin, leucovorin and 5-FU
‡ paclitaxel and cisplatin
§ 5-FU and leucovorin
¶ 5-FU and MMC
Figure 4 Kaplan-Meier plot of OS for patients receiving
palliative chemotherapy. Median OS of 13 patients receiving
palliative chemotherapy was 8.03 months (95% CI: 6.59-9.47, range:
0.63-40.8 months)
Figure 5 Kaplan-Meier plot of PFS for patients receiving
palliative chemotherapy. Median PFS of 13 patients receiving
palliative chemotherapy was 3.47 months, respectively (95% CI: 0.65-
6.29, range: 0.63 - 35.43 months, respectively)
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formance and active treatment, including palliative gas-
trectomy and chemotherapy. In a xenograft model of
AFP-producing gastric cancer, 5-FU, doxorubicin, and
epirubicin did not induce suppression of tumor growth;
h o w e v e r ,M M Ca n dc i s p l a t i nm a yb ea c t i v et os o m e
extent [21]. Most patients received platinum based che-
motherapy. The disease control rate was 50%. In parti-
cular, a patient with initial stage IV and showing partial
response to 1
st line palliative chemotherapy (cisplatin
and 5-FU) showed progression after 26.2 months. The
patient also showed partial response to 2
nd line cisplatin
and paclitaxel.
HAC of the stomach was revised in all of these cases;
due to the rare incidence of this neoplasm, the main
clinical characteristics of these types of tumors are
described in a published report [22]. The majority of
patients were male and the average age was about 64
years old. The antrum and pylorus were the most com-
mon primary sites of tumors and their AFP levels were
much higher than normal. Our data also show male pre-
dominance (11:2) and the lower-third was the most
common site (65%); 63% of patients checked for serum
AFP level had elevated AFP, and 61% of patients were
diagnosed as stage I, II, or III, and the other was diag-
nosed as stage IV. Relapse rate of patients with early
stage or locally advanced stage was 47%.
This study also has some limitations. The first is that
this is a retrospective study of a single center; thus, we
cannot exclude the possibility of a selection bias. The sec-
ond, sample size is too small. Nevertheless, considering
the rare incidence of HAC and previous case reports or
case series, this study presents the first report that focused
on relapse rate of early or advanced stage HAC and
response rate to chemotherapy and treatment outcome of
terminal stage HAC.
Conclusion
I nc o n c l u s i o n ,H A Co ft h es t o m a c hi sar a r et y p eo f
adenocarcinoma, with an incidence of 0.17% of gastric
cancer cases. Of total HAC patients, 60% of patients
were diagnosed with early stage or locally advanced
stage, and 47% of them relapsed. All patients with early
stage gastric cancer were cured. Therefore, early detec-
tion of this type of cancer is of critical importance to
patient prognosis. Additional studies to reveal the biol-
ogy and outcome of this tumor are warranted.
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